Treatment of refractory blistering autoimmune diseases with mycophenolic acid

Angelo V. Marzano, Federica Dassoni, Ruggero Caputo

Research output: Contribution to journalArticle

Abstract

Background: Immunosuppressive drugs are used as steroid-sparing agents in the management of blistering autoimmune diseases. Mycophenolic acid (MPA) is a relatively new adjuvant drug that selectively inhibits T and B lymphocyte proliferation by suppressing de novo purine synthesis. Objective: To evaluate the efficacy of MPA in refractory blistering autoimmune diseases and the safety profile of a recent formulation, enteric-coated mycophenolate sodium (EC-MPS), in comparison with mycophenolate mofetil (MMF). Patients and methods: Twelve patients with various bullous dermatoses (three pemphigus vulgaris, one pemphigus herpetiformis, three bullous pemphigoid (BP), two cicatricial pemphigoid (CP) and three epidermolysis bullosa acquisita (EBA)) were enrolled in the study. In 10 cases, MPA was administered in combination with systemic corticosteroids, while in two patients with severe diabetes mellitus MPA was employed as monotherapy. The total time on MPA varied from 2 to 8 months. Four patients were given MMF (2000 mg daily), seven received EC-MPS (1440 mg daily) and one received both sequentially. Results: Complete remission, lasting for a mean time of 6.1 months, was achieved in 10 patients. Partial remission was obtained in two patients with disseminated CP and EBA. Both MMF and EC-MPS were well tolerated, but the latter was better in terms of gastrointestinal adverse effects. Conclusions: MPA may be proposed as a first-line adjuvant agent for pemphigus as well as for refractory BP and CP. MPA monotherapy has to be considered in selected cases of BP and pemphigus. The highly promising results obtained in EBA suggest a future key role for MPA in the management of this disease.

Original languageEnglish
Pages (from-to)370-376
Number of pages7
JournalJournal of Dermatological Treatment
Volume17
Issue number6
DOIs
Publication statusPublished - Dec 2006

Fingerprint

Mycophenolic Acid
Autoimmune Diseases
Pemphigus
Epidermolysis Bullosa Acquisita
Benign Mucous Membrane Pemphigoid
Bullous Pemphigoid
Therapeutics
Vesiculobullous Skin Diseases
Immunosuppressive Agents
Disease Management

Keywords

  • Blistering autoimmune diseases
  • Enteric-coated mycophenolate sodium
  • Mycophenolate mofetil
  • Mycophenolic acid

ASJC Scopus subject areas

  • Dermatology

Cite this

Treatment of refractory blistering autoimmune diseases with mycophenolic acid. / Marzano, Angelo V.; Dassoni, Federica; Caputo, Ruggero.

In: Journal of Dermatological Treatment, Vol. 17, No. 6, 12.2006, p. 370-376.

Research output: Contribution to journalArticle

@article{318bed634ec349ada40319328e433c30,
title = "Treatment of refractory blistering autoimmune diseases with mycophenolic acid",
abstract = "Background: Immunosuppressive drugs are used as steroid-sparing agents in the management of blistering autoimmune diseases. Mycophenolic acid (MPA) is a relatively new adjuvant drug that selectively inhibits T and B lymphocyte proliferation by suppressing de novo purine synthesis. Objective: To evaluate the efficacy of MPA in refractory blistering autoimmune diseases and the safety profile of a recent formulation, enteric-coated mycophenolate sodium (EC-MPS), in comparison with mycophenolate mofetil (MMF). Patients and methods: Twelve patients with various bullous dermatoses (three pemphigus vulgaris, one pemphigus herpetiformis, three bullous pemphigoid (BP), two cicatricial pemphigoid (CP) and three epidermolysis bullosa acquisita (EBA)) were enrolled in the study. In 10 cases, MPA was administered in combination with systemic corticosteroids, while in two patients with severe diabetes mellitus MPA was employed as monotherapy. The total time on MPA varied from 2 to 8 months. Four patients were given MMF (2000 mg daily), seven received EC-MPS (1440 mg daily) and one received both sequentially. Results: Complete remission, lasting for a mean time of 6.1 months, was achieved in 10 patients. Partial remission was obtained in two patients with disseminated CP and EBA. Both MMF and EC-MPS were well tolerated, but the latter was better in terms of gastrointestinal adverse effects. Conclusions: MPA may be proposed as a first-line adjuvant agent for pemphigus as well as for refractory BP and CP. MPA monotherapy has to be considered in selected cases of BP and pemphigus. The highly promising results obtained in EBA suggest a future key role for MPA in the management of this disease.",
keywords = "Blistering autoimmune diseases, Enteric-coated mycophenolate sodium, Mycophenolate mofetil, Mycophenolic acid",
author = "Marzano, {Angelo V.} and Federica Dassoni and Ruggero Caputo",
year = "2006",
month = "12",
doi = "10.1080/09546630600964999",
language = "English",
volume = "17",
pages = "370--376",
journal = "Journal of Dermatological Treatment",
issn = "0954-6634",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Treatment of refractory blistering autoimmune diseases with mycophenolic acid

AU - Marzano, Angelo V.

AU - Dassoni, Federica

AU - Caputo, Ruggero

PY - 2006/12

Y1 - 2006/12

N2 - Background: Immunosuppressive drugs are used as steroid-sparing agents in the management of blistering autoimmune diseases. Mycophenolic acid (MPA) is a relatively new adjuvant drug that selectively inhibits T and B lymphocyte proliferation by suppressing de novo purine synthesis. Objective: To evaluate the efficacy of MPA in refractory blistering autoimmune diseases and the safety profile of a recent formulation, enteric-coated mycophenolate sodium (EC-MPS), in comparison with mycophenolate mofetil (MMF). Patients and methods: Twelve patients with various bullous dermatoses (three pemphigus vulgaris, one pemphigus herpetiformis, three bullous pemphigoid (BP), two cicatricial pemphigoid (CP) and three epidermolysis bullosa acquisita (EBA)) were enrolled in the study. In 10 cases, MPA was administered in combination with systemic corticosteroids, while in two patients with severe diabetes mellitus MPA was employed as monotherapy. The total time on MPA varied from 2 to 8 months. Four patients were given MMF (2000 mg daily), seven received EC-MPS (1440 mg daily) and one received both sequentially. Results: Complete remission, lasting for a mean time of 6.1 months, was achieved in 10 patients. Partial remission was obtained in two patients with disseminated CP and EBA. Both MMF and EC-MPS were well tolerated, but the latter was better in terms of gastrointestinal adverse effects. Conclusions: MPA may be proposed as a first-line adjuvant agent for pemphigus as well as for refractory BP and CP. MPA monotherapy has to be considered in selected cases of BP and pemphigus. The highly promising results obtained in EBA suggest a future key role for MPA in the management of this disease.

AB - Background: Immunosuppressive drugs are used as steroid-sparing agents in the management of blistering autoimmune diseases. Mycophenolic acid (MPA) is a relatively new adjuvant drug that selectively inhibits T and B lymphocyte proliferation by suppressing de novo purine synthesis. Objective: To evaluate the efficacy of MPA in refractory blistering autoimmune diseases and the safety profile of a recent formulation, enteric-coated mycophenolate sodium (EC-MPS), in comparison with mycophenolate mofetil (MMF). Patients and methods: Twelve patients with various bullous dermatoses (three pemphigus vulgaris, one pemphigus herpetiformis, three bullous pemphigoid (BP), two cicatricial pemphigoid (CP) and three epidermolysis bullosa acquisita (EBA)) were enrolled in the study. In 10 cases, MPA was administered in combination with systemic corticosteroids, while in two patients with severe diabetes mellitus MPA was employed as monotherapy. The total time on MPA varied from 2 to 8 months. Four patients were given MMF (2000 mg daily), seven received EC-MPS (1440 mg daily) and one received both sequentially. Results: Complete remission, lasting for a mean time of 6.1 months, was achieved in 10 patients. Partial remission was obtained in two patients with disseminated CP and EBA. Both MMF and EC-MPS were well tolerated, but the latter was better in terms of gastrointestinal adverse effects. Conclusions: MPA may be proposed as a first-line adjuvant agent for pemphigus as well as for refractory BP and CP. MPA monotherapy has to be considered in selected cases of BP and pemphigus. The highly promising results obtained in EBA suggest a future key role for MPA in the management of this disease.

KW - Blistering autoimmune diseases

KW - Enteric-coated mycophenolate sodium

KW - Mycophenolate mofetil

KW - Mycophenolic acid

UR - http://www.scopus.com/inward/record.url?scp=34250184467&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250184467&partnerID=8YFLogxK

U2 - 10.1080/09546630600964999

DO - 10.1080/09546630600964999

M3 - Article

C2 - 17853312

AN - SCOPUS:34250184467

VL - 17

SP - 370

EP - 376

JO - Journal of Dermatological Treatment

JF - Journal of Dermatological Treatment

SN - 0954-6634

IS - 6

ER -